CLINICAL TRIALS PROFILE FOR TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

All Clinical Trials for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01378299 ↗	CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy	Completed	Baylor College of Medicine	Phase 1	2011-10-01	Testosterone (T) replacement prevents bone loss and relieves symptoms associated with androgen deficiency in male patients with hypogonadism, but at the expense of an increase in prostate-related adverse events and in the hematocrit values above the normal which may lead to bad circulatory outcomes. Most of the effects of T on the male skeleton are mediated by its conversion to estradiol (E2) by the enzyme aromatase. Genetic variations in the aromatase (CYP19A1) gene result in enzymes with variable activity and variable levels of E2 and T. This project is designed to determine if genetic variations in the CYP19A1 gene will result in differences in the skeletal response and incidence of side effects from T treatment in patients with low T. A large number of male Veterans are on T. Results from this project will help identify patients who would benefit from the therapy from those at risk for side effects, and would definitely have an impact in the future care of these patients and male patients in general once genetic profiling becomes part of the standard of care.
NCT01378299 ↗	CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy	Completed	VA Office of Research and Development	Phase 1	2011-10-01	Testosterone (T) replacement prevents bone loss and relieves symptoms associated with androgen deficiency in male patients with hypogonadism, but at the expense of an increase in prostate-related adverse events and in the hematocrit values above the normal which may lead to bad circulatory outcomes. Most of the effects of T on the male skeleton are mediated by its conversion to estradiol (E2) by the enzyme aromatase. Genetic variations in the aromatase (CYP19A1) gene result in enzymes with variable activity and variable levels of E2 and T. This project is designed to determine if genetic variations in the CYP19A1 gene will result in differences in the skeletal response and incidence of side effects from T treatment in patients with low T. A large number of male Veterans are on T. Results from this project will help identify patients who would benefit from the therapy from those at risk for side effects, and would definitely have an impact in the future care of these patients and male patients in general once genetic profiling becomes part of the standard of care.
NCT01750398 ↗	Bipolar Androgen-based Therapy for Prostate Cancer (BAT)	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	2013-01-01	The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the effect of alternating therapy on quality of life and metabolic changes associated with androgen-deprivation therapy.
NCT01750398 ↗	Bipolar Androgen-based Therapy for Prostate Cancer (BAT)	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	2013-01-01	The purpose of this study is to determine the safety and clinical effects of alternating androgen deprivation therapy with testosterone therapy in men with recurrent prostate cancer as first line hormonal therapy, to assess the effect of alternating therapy on quality of life and metabolic changes associated with androgen-deprivation therapy.

Clinical Trial Conditions for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

Condition Name

Condition Name for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Intervention	Trials
Recurrent Prostate Cancer	1
Hypogonadism	1

Condition MeSH

Condition MeSH for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Intervention	Trials
Prostatic Neoplasms	1
Hypogonadism	1

Clinical Trial Locations for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

Trials by Country

Trials by Country for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Location	Trials
United States	3

Trials by US State

Trials by US State for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Location	Trials
Maryland	1
Texas	1
New Mexico	1

Clinical Trial Progress for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

Clinical Trial Phase

Clinical Trial Phase for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

Sponsor Name

Sponsor Name for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Sponsor	Trials
VA Office of Research and Development	1
Sidney Kimmel Comprehensive Cancer Center	1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	1

Sponsor Type

Sponsor Type for TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Sponsor	Trials
Other	3
U.S. Fed	1

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE Market Analysis and Financial Projection

Last updated: May 2, 2026

What is the current clinical-trials landscape, market size, and outlook for testosterone cypionate–estradiol cypionate?

Clinical trials update: what evidence exists for testosterone cypionate–estradiol cypionate?

Testosterone cypionate plus estradiol cypionate is an approved combination drug product in multiple jurisdictions. Trial activity is mostly (1) safety and pharmacokinetic work for specific formulations and dosing regimens, and (2) post-approval or comparative studies tied to local regulatory requirements and manufacturing changes.

At the level of global registries and regulator-facing publications, the most consistently trackable signals for this specific pairing tend to come from:

• Formulation- and dose-finding studies (including interval adjustments and injection-site tolerability endpoints).
• Bioequivalence or pharmacokinetic bridging when manufacturers change concentration, solvent system, or presentation.
• Therapeutic studies in target populations aligned to the approved indications for combined androgen-estrogen replacement in hypogonadal men where estradiol is prescribed to manage bone and sexual function parameters.

However, without a specific identifier (brand name, sponsor, or NCT/CTRI/EudraCT record), trial listings for “testosterone cypionate–estradiol cypionate” often fragment across synonyms, local trade names, and formulation variants. Clinical-trials reporting for this combination therefore behaves like a label-linked dataset more than a single coherent “drug-development pipeline.”

Implication for diligence: clinical-trials value for this exact combination is best assessed by crosswalking (a) the local brand’s label language and (b) the manufacturer’s submission history into registry records, rather than by relying on a single search term.

---

Market analysis: how big is the market and where does demand concentrate?

Testosterone cypionate is the anchor product class in this combination. Estradiol cypionate in combination demand is typically smaller and rides the same channel access, prescriber education, and reimbursement structure as testosterone replacement therapy (TRT) overall.

Demand drivers

• Aging demographics and androgen deficiency prevalence
• Chronic-treatment model with repeat prescriptions
• Regulatory and payer preferences for injectable regimens in specific patient groups
• Off-label estrogen co-administration in some TRT practices, which increases the willingness to use fixed-dose combinations where reimbursable

Price and channel structure

For fixed-dose androgen-estrogen injectables:

• Pricing is usually less dependent on day-level pharmacology and more dependent on availability, wholesaler contracts, and tendering in national health systems.
• In private markets, the combination competes against separate testosterone and estradiol prescriptions, not against placebo or alternative APIs.

Competitive set

The realistic competitor set is not “other androgen-estrogen cypionate products” only. It includes:

• Separate injections (testosterone cypionate plus estradiol formulations that may be different salts)
• Other testosterone injection schedules (including other esters)
• Non-injectable testosterone products in payer-supported formularies, where estrogen co-therapy is managed separately

---

Projection: what is the forward trajectory for testosterone cypionate–estradiol cypionate?

Near-term volume growth in established markets follows TRT category dynamics: demographic tailwinds and increased diagnosis, moderated by guideline-driven monitoring and payer utilization controls.

A mid-cycle projection for the specific combination product should be built on three measurable vectors:

1. TRT category growth in treated populations (diagnosis and persistence)
2. Share capture vs separated prescribing (whether the fixed-dose combination is preferred in formularies and clinics)
3. Manufacturing and supply continuity (injectables are sensitive to lot release and sourcing constraints)

Scenario outlook (business planning view)

• Base case: modest share retention within TRT injectables; growth tracks TRT market expansion with stability in substitution risk from separate prescribing.
• Upside case: formulary wins in countries or health systems that prefer fixed-dose androgen-estrogen regimens for monitoring simplicity.
• Downside case: substitution to separate dosing plus shifts to preferred testosterone forms in payer formularies, coupled with supply disruptions.

---

What will change the risk profile? Key watch items

For this combination, the most decision-relevant updates typically come from:

• Regulatory label updates tied to safety signals (especially erythrocytosis and cardiovascular risk monitoring requirements for testosterone products).
• Bioequivalence requirements triggered by manufacturing site changes.
• Availability of generic testosterone cypionate affecting total class economics and channel leverage, which can pressure combination pricing.

---

Key Takeaways

• Clinical-trials visibility for testosterone cypionate–estradiol cypionate is often label- and formulation-linked rather than tied to a single global development program.
• Market demand is driven primarily by the testosterone cypionate TRT category; estradiol cypionate co-use is usually managed by payer and prescriber practices that determine whether fixed-dose combinations gain share versus separated prescribing.
• Projection is best framed as a function of TRT category growth plus fixed-dose combination share retention, with material sensitivity to formularies and supply continuity.

---

FAQs

1. Is testosterone cypionate–estradiol cypionate a single investigational drug or an established combination?
   It is an established combination product in multiple markets; clinical evidence often tracks formulation, dosing, and post-approval needs rather than a single ongoing pivotal program.

2. What endpoints matter most in trials for this combination?
   Typical focus includes pharmacokinetics (testosterone and estradiol exposure), safety (hematocrit/erythrocytosis, injection-site events), and tolerability over dosing intervals.

3. What is the main competitive threat to the fixed-dose combination?
   Separate prescribing of testosterone and estradiol using different salt formulations, driven by payer formularies and prescriber flexibility.

4. How should investors model growth?
   Model growth off the broader TRT category, then add a share layer for fixed-dose combination preference versus separate dosing, and discount for supply or tender volatility.

5. What regulatory events most affect commercial outlook?
   Label changes tied to testosterone safety monitoring, bioequivalence submissions for manufacturing changes, and any restrictions affecting injectable androgen-estrogen products.

---

References

[1] FDA. Drug Approval Reports and product labeling resources for testosterone formulations (accessed 2026).
[2] EMA. European public assessment and medicinal product information for testosterone and estrogen combination or linked products (accessed 2026).
[3] ClinicalTrials.gov. Search results for testosterone cypionate and estradiol cypionate combination-related records under sponsor and product-name synonyms (accessed 2026).
[4] WHOCC. ATC classification for testosterone and estradiol-related products and therapeutic group mapping (accessed 2026).